Table 3.
Patient characteristics by duration of diabetes
| Diabetes duration (yrs) | n (%)a | Mean±SD HbA1c (%) | Concomitant disease/ complication (%)b | Achieved HbA1c <7.0% (%)b | OAD (%)b | Insulin + OAD (%)b | GLP-1 RA + OAD (%)b |
|---|---|---|---|---|---|---|---|
| <1 |
36,337 (15.22) |
8.12±1.99 |
12,663 (34.85) |
11,007 (30.29) |
26,372 (72.58) |
9909 (27.27) |
56 (0.15) |
| ≥1-5 |
102,550 (42.97) |
7.66±1.61 |
45,533 (44.40) |
36,331 (35.43) |
75,459 (73.58) |
26,896 (26.23) |
195 (0.19) |
| ≥5-10 |
55,744 (23.36) |
7.84±1.66 |
34,374 (61.67) |
16,915 (30.34) |
34,446 (61.79) |
21,159 (37.96) |
139 (0.25) |
| ≥10 |
44,003 (18.44) |
8.09±1.76 |
31,607 (71.83) |
11,575 (26.31) |
20,933 (47.57) |
23,006 (52.28) |
64 (0.15) |
| P valuec | <0.0001 | <0.0001 | <0.0001 | <0.0001 | NS | NS |
aPercentage of patients among the full population; bPercentage of patients among the patients with particular diabetes duration; cANOVA and chi-square test were used as appropriate.
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; NS = not significant; OAD, oral antidiabetes drug; SD, standard deviation.